IBDEI0IR ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8440,2)
 ;;=^5015763
 ;;^UTILITY(U,$J,358.3,8441,0)
 ;;=N32.81^^39^398^84
 ;;^UTILITY(U,$J,358.3,8441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8441,1,3,0)
 ;;=3^Overactive Bladder
 ;;^UTILITY(U,$J,358.3,8441,1,4,0)
 ;;=4^N32.81
 ;;^UTILITY(U,$J,358.3,8441,2)
 ;;=^5015652
 ;;^UTILITY(U,$J,358.3,8442,0)
 ;;=Q61.2^^39^398^88
 ;;^UTILITY(U,$J,358.3,8442,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8442,1,3,0)
 ;;=3^Polycystic Kidney,Adult Type
 ;;^UTILITY(U,$J,358.3,8442,1,4,0)
 ;;=4^Q61.2
 ;;^UTILITY(U,$J,358.3,8442,2)
 ;;=^5018796
 ;;^UTILITY(U,$J,358.3,8443,0)
 ;;=N41.1^^39^398^92
 ;;^UTILITY(U,$J,358.3,8443,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8443,1,3,0)
 ;;=3^Prostatitis,Chronic
 ;;^UTILITY(U,$J,358.3,8443,1,4,0)
 ;;=4^N41.1
 ;;^UTILITY(U,$J,358.3,8443,2)
 ;;=^186931
 ;;^UTILITY(U,$J,358.3,8444,0)
 ;;=N11.9^^39^398^100
 ;;^UTILITY(U,$J,358.3,8444,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8444,1,3,0)
 ;;=3^Pyelonephritis,Chronic,Unspec
 ;;^UTILITY(U,$J,358.3,8444,1,4,0)
 ;;=4^N11.9
 ;;^UTILITY(U,$J,358.3,8444,2)
 ;;=^5015574
 ;;^UTILITY(U,$J,358.3,8445,0)
 ;;=N20.9^^39^398^118
 ;;^UTILITY(U,$J,358.3,8445,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8445,1,3,0)
 ;;=3^Urinary Calculus,Unspec
 ;;^UTILITY(U,$J,358.3,8445,1,4,0)
 ;;=4^N20.9
 ;;^UTILITY(U,$J,358.3,8445,2)
 ;;=^5015610
 ;;^UTILITY(U,$J,358.3,8446,0)
 ;;=R97.20^^39^398^31
 ;;^UTILITY(U,$J,358.3,8446,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8446,1,3,0)
 ;;=3^Elevated PSA
 ;;^UTILITY(U,$J,358.3,8446,1,4,0)
 ;;=4^R97.20
 ;;^UTILITY(U,$J,358.3,8446,2)
 ;;=^334262
 ;;^UTILITY(U,$J,358.3,8447,0)
 ;;=N52.36^^39^398^36
 ;;^UTILITY(U,$J,358.3,8447,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8447,1,3,0)
 ;;=3^Erectile Dysfunction After Interstitial Seed Therapy
 ;;^UTILITY(U,$J,358.3,8447,1,4,0)
 ;;=4^N52.36
 ;;^UTILITY(U,$J,358.3,8447,2)
 ;;=^5138933
 ;;^UTILITY(U,$J,358.3,8448,0)
 ;;=N52.37^^39^398^37
 ;;^UTILITY(U,$J,358.3,8448,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8448,1,3,0)
 ;;=3^Erectile Dysfunction After Prostate Ablative Therapy
 ;;^UTILITY(U,$J,358.3,8448,1,4,0)
 ;;=4^N52.37
 ;;^UTILITY(U,$J,358.3,8448,2)
 ;;=^5138934
 ;;^UTILITY(U,$J,358.3,8449,0)
 ;;=N52.35^^39^398^38
 ;;^UTILITY(U,$J,358.3,8449,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8449,1,3,0)
 ;;=3^Erectile Dysfunction After Radiation Therapy
 ;;^UTILITY(U,$J,358.3,8449,1,4,0)
 ;;=4^N52.35
 ;;^UTILITY(U,$J,358.3,8449,2)
 ;;=^5138932
 ;;^UTILITY(U,$J,358.3,8450,0)
 ;;=R31.21^^39^398^58
 ;;^UTILITY(U,$J,358.3,8450,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8450,1,3,0)
 ;;=3^Hematuria,Microscopic,Asymptomatic
 ;;^UTILITY(U,$J,358.3,8450,1,4,0)
 ;;=4^R31.21
 ;;^UTILITY(U,$J,358.3,8450,2)
 ;;=^5139198
 ;;^UTILITY(U,$J,358.3,8451,0)
 ;;=R31.29^^39^398^59
 ;;^UTILITY(U,$J,358.3,8451,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8451,1,3,0)
 ;;=3^Hematuria,Microscopic,Other
 ;;^UTILITY(U,$J,358.3,8451,1,4,0)
 ;;=4^R31.29
 ;;^UTILITY(U,$J,358.3,8451,2)
 ;;=^5019327
 ;;^UTILITY(U,$J,358.3,8452,0)
 ;;=R39.198^^39^398^72
 ;;^UTILITY(U,$J,358.3,8452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8452,1,3,0)
 ;;=3^Micturition,Oth Difficulties
 ;;^UTILITY(U,$J,358.3,8452,1,4,0)
 ;;=4^R39.198
 ;;^UTILITY(U,$J,358.3,8452,2)
 ;;=^5019347
 ;;^UTILITY(U,$J,358.3,8453,0)
 ;;=R39.191^^39^398^74
 ;;^UTILITY(U,$J,358.3,8453,1,0)
 ;;=^358.31IA^4^2
